Literature DB >> 26869578

Voluntary pulmonary function screening identifies high rates of undiagnosed asymptomatic chronic obstructive pulmonary disease.

Shengyu Wang1, Wei Gong2, Yao Tian2.   

Abstract

Chronic obstructive pulmonary disease (COPD) is projected to be the third leading cause of death by 2020. Early detection and screening may alter the course and prognosis associated with lung disease. We investigated the effectiveness of a voluntary public lung function screening program and factors that had a predictive value for asymptomatic COPD in Xi'an, China. Pulmonary function testing (PFT) was conducted on volunteers recruited from four community centers in Xi'an, China, between July and August 2012. Participants underwent three forced vital capacity maneuvers. The maneuver with the best forced expiratory volume in first second was retained. Participants filled out a medical history and environmental exposure survey before undergoing the PFT. Patients who self-reported lung disease on the health survey were excluded from the analysis. Logistical regression was used to determine associations with airway obstruction. A total of 803 volunteers participated in this study, and 33 subjects were excluded as the participants did not meet the requirements of PFT. Of the 770 volunteers, 44 participants had been diagnosed with chronic respiratory diseases previously, and 144 participants (18.7%) met COPD criteria. Four hundred forty-four participants did not self-report any respiratory symptoms, and the remaining 282 participants self-reported respiratory symptoms. Of the asymptomatic participants, 98 volunteers had PFT results that were consistent with COPD and 68.1% of asymptomatic participants were undiagnosed. A greater percentage of women than men had moderate or severe airway obstruction (p = 0.004).Only smoking status (odds ratio = 2.64, 95% confidence interval 1.20-6.04) was associated with asymptomatic COPD. Voluntary public lung function screening programs in China are likely to identify a large number of undiagnosed, asymptomatic COPD. Smoking status is associated with airway obstruction and a greater percentage of women than men had moderate or severe airway obstruction.
© The Author(s) 2016.

Entities:  

Keywords:  Pulmonary function test; airway obstruction; asymptomatic COPD; spirometry; voluntary screening

Mesh:

Year:  2016        PMID: 26869578      PMCID: PMC5734600          DOI: 10.1177/1479972316631136

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  30 in total

1.  Global burden of disease 2005: call for collaborators.

Authors:  Christopher Jl Murray; Alan D Lopez; Robert Black; Colin D Mathers; Kenji Shibuya; Majid Ezzati; Joshua A Salomon; Catherine M Michaud; Neff Walker; Theo Vos
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

Review 2.  Long-term effects of ambient air pollution on lung function: a review.

Authors:  Thomas Götschi; Joachim Heinrich; Jordi Sunyer; Nino Künzli
Journal:  Epidemiology       Date:  2008-09       Impact factor: 4.822

3.  Health impact: Breathless.

Authors:  Amber Dance
Journal:  Nature       Date:  2012-09-27       Impact factor: 49.962

Review 4.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

5.  Epidemiology Standardization Project (American Thoracic Society).

Authors:  B G Ferris
Journal:  Am Rev Respir Dis       Date:  1978-12

6.  Prevalence of asthma and other allergic diseases in an adolescent population: association with gender and race.

Authors:  J K Fagan; P A Scheff; D Hryhorczuk; V Ramakrishnan; M Ross; V Persky
Journal:  Ann Allergy Asthma Immunol       Date:  2001-02       Impact factor: 6.347

7.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

8.  Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study.

Authors:  Ana Maria B Menezes; Rogelio Perez-Padilla; José Roberto B Jardim; Adriana Muiño; Maria Victorina Lopez; Gonzalo Valdivia; Maria Montes de Oca; Carlos Talamo; Pedro C Hallal; Cesar G Victora
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

Review 9.  Screening for and early detection of chronic obstructive pulmonary disease.

Authors:  Joan B Soriano; Jan Zielinski; David Price
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321

10.  Age-sex incidence in symptomatic allergies: an excess of females in the child-bearing years.

Authors:  P J Wormald
Journal:  J Hyg (Lond)       Date:  1977-08
View more
  3 in total

1.  The Efficiency Index (EFFi), based on volumetric capnography, may allow for simple diagnosis and grading of COPD.

Authors:  Linnea Jarenbäck; Ellen Tufvesson; Jaro Ankerst; Leif Bjermer; Björn Jonson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-06-27

2.  Patients with more comorbidities have better detection of chronic conditions, but poorer management and control: findings from six middle-income countries.

Authors:  Grace Sum; Gerald Choon-Huat Koh; Stewart W Mercer; Lim Yee Wei; Azeem Majeed; Brian Oldenburg; John Tayu Lee
Journal:  BMC Public Health       Date:  2020-01-06       Impact factor: 3.295

3.  Study to evaluate the effectiveness and cost-effectiveness of different screening strategies for identifying undiagnosed COPD among residents (≥40 years) in four cities in China: protocol for a multicentre cross-sectional study on behalf of the Breathe Well group.

Authors:  Zihan Pan; Andrew P Dickens; Chunhua Chi; Xia Kong; Alexandra Enocson; Peymane Adab; Kar Keung Cheng; Alice J Sitch; Sue Jowett; Rachel Jordan
Journal:  BMJ Open       Date:  2020-11-27       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.